OliX

팝업닫기

Refusal of Unauthorized Collection of E-mail Addresses

We do not allow the unauthorized collection of e-mail addresses listed on our website.Persons engaging in unauthorized collection with e-mail address collection programs or other technical devices will be subject to criminal prosecution in accordance with the Act on Information & Communications Network Utilization and Information Protection.

Contact Us

form mail list
Name *
Tel *	- -
E-mail *	@
Subject *
Contents
File1
File2
Spam Check*	* 왼쪽의 자동등록방지 코드를 입력하세요.

Consent to Collect and Use Personal Information

I agree to the use of personal information collected from myself or other legitimate sources.

Information collected : Name, Phone number, E-mail, Message
Purpose of collection and use : conducting certain services or activities including but not limited to replying to inquiries and maintaining business records.
Period of retention and use : Personal information is to be discarded after the purpose of collection and use has been achieved.

- Personal Information shall be discarded without delay once the purpose of collection and use has been achieved; provided however that, if an obligation to retain such information exists under applicable law(s), the information shall be retained for a period of time as required by such law(s).
- Even prior to the purpose of use and collection being achieved, personal information may be discarded upon request via email sent to olixpharma@olixpharma.com. Please note, however, that your use of the services herein may be limited.

※ You have the right not to consent to the collection and use of your personal information, in which event your use of the services may be limited.

I agree to the terms and conditions.

Platform Technology

RNAi platform development

Lead compound discovery

Pulmonology / Neurology

Pharmacological research on OliX RNAi compounds for respiratory and neurological diseases

Ophthalmology

Pharmacological research on OliX RNAi compounds for ocular diseases

Animal Research

Testing efficacy of oligonucleotide therapeutics using animal models

Analytics

Develop analytical methods for therapeutic candidates to determine purity and stability in support of nonclinical and clinical studies

PK/TK

Develop bioanalytical methods to quantitate therapeutic candidates in biological matrices for pharmacokinetic and toxicokinetic (PK/TK) studies

CMC

Manage manufacturing, analytics and quality of therapeutic candidates

Toxicology

Conduct safety evaluation and toxicokinetic assessment of therapeutic candidates through nonclinical studies

Clinical

Establish clinical development plans for therapeutic candidates and conduct clinical studies

Management

Business Management

Purchasing

General Affairs

Facility Management

Contingency Planning

Planning

Budget/Performance Management

Mid to Long-term Business Goals/Strategy Planning

Accounting & Finance

Make official announcements about business contents, financial condition, business performance etc.

Stabilize Internal Accounting Control System

IT

IT Infrastructure Management

IT Helpdesk

Human Resources

HR Policy/System Establishment, Organization/Job Design

Recruitment/HR Management

Performance Management, Employee Welfare

HR Development

Legal Affairs

Prevent, respond, handle legal disputes

Provide risk management and compliance support

Develop IP strategies for core technologies

Quality Assurance(QA)

Verify pharmaceutical R&D processes and results

Ensure product to meet the established quality standards

Business Development

Develop/Maintain Client Relationships

Execute Licensing Agreements

New Business/Strategy Planning

Communications

Provide investment information in a timely manner to increase company value

Promote management activities and establish internal/external communication strategies

Create positive corporate culture through various in-house activities and employee education

Home
R&D

R&D

주요 파이프라인

주요 파이프라인

Pipeline
OLX101A
OLX104C
OLX301A
OLX301D
OLX702A
OLX703A

OLX301D

Subretinal Fibrosis / wet AMD Treatment

OLX301D is designed to target CTGF mRNA and inhibit the progression of subretinal fibrosis and neovascularization.
Many times, subretinal fibrosis is the direct cause of vision loss. As there are no approved drugs and the therapeutics is expected to,
be effective in approximately 30% of wet AMD patients who do not respond to anti-VEGF treatments,
the program is expected to address a significant portion of unmet needs once developed.

* CTGF(Connective Tissue Growth Factor): a protein regulating proliferation and tissue repair

* VEGF(Vascular Endothelial Growth Factor): a signal protein stimulating the formation of new blood vessels

Target RNA: CTGF

Administration Route: Intravitreal Injection

Subretinal Fibrosis (SRF)

Subretinal fibrosis, which occurs in most cases of wet AMD, is known as the leading cause of irreversible vision loss. During neovascularization, fibrosis occurs along with local destruction of the RPE and choroidal vessels, permanently impairing the macula.

Preclinical Data

Development Status

Expanded License and Collaboration Agreement with Théa Open Innovation (Territory: Worldwide excl. Asia-Pacific) (20.10)
Efficacy identified in animal models with SRF and wet AMD
Confirmation of superior synergistic efficacy with conventional anti-VEGF treatment

Conference Presentation

2021 CSHL(Cold Spring Harbor Laboratory)-Nucleic Acid Therapies (21.03)
2021 OTS (Oligonucleotide Therapeutics Society) (21.09)